logo

For the Inventor, By the Inventor

Arlington, MA, United States of America

Boris Engels

This inventor holds 16 USPTO granted patents and 12 published patent applications and 7 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Novartis Ag, University of Pennsylvania, Dana-Farber-Cancer Institute Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Boris Engels. Retrieved from https://idiyas.com/inventor/boris-engels

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 48(Granted Patents)


Location History:

  • Cambridge, MA (US) (2020)
  • Arlington, MA (US) (2019 - 2024)

Company Filing History:

goldMedal16 out of 3,978 
 
Novartis Ag
 patents
silverMedal13 out of 2,659 
 
University of Pennsylvania
 patents
bronzeMedal2 out of 1,268 
 
Dana-Farber-Cancer Institute Inc.
 patents
4. 2 out of 3,078 
 
Harvard College
 patents
where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptor
Cancer Treatment
CD19
CD20
PD-L1 Inhibitor
Mesothelin
Nucleic Acid Molecules
Adoptive Immunotherapy
Cytotoxic Cells
Combined Therapy
Human Mesothelin
Regulatable Receptor
16 patents (USPTO):Explore Patents
1. 12594321 - Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer (2026-04-07),
2. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),
3. 12344651 - CD19 and CD22 chimeric antigen receptors and uses thereof (2025-07-01),
4. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),
5. 11999794 - Human mesothelin chimeric antigen receptors and uses thereof (2024-06-04),
6. 11981731 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2024-05-14),
7. 11975026 - CD19 and CD22 chimeric antigen receptors and uses thereof (2024-05-07),
8. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),
9. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),
10. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),
11. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),
12. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),
13. 10640569 - Human mesothelin chimeric antigen receptors and uses thereof (2020-05-05),
14. 10577417 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2020-03-03),
15. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2020-01-07),

Title: Boris Engels: Pioneering Innovator in Technology

Introduction: Boris Engels, a distinguished inventor based in Arlington, MA (US), has carved a remarkable path in the realm of technology with his groundbreaking inventions.

Latest Patents: Boris Engels has 12 patents to his name, with his latest innovations including "Human mesothelin chimeric antigen receptors and uses thereof" and "Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy". These patents showcase his commitment to advancing medical technology for the betterment of society.

Career Highlights: Throughout his illustrious career, Boris has worked with renowned institutions such as Novartis AG and the University of Pennsylvania, where he has made significant contributions to the field of technology and healthcare. His relentless dedication to innovation has led to the development of cutting-edge solutions.

Collaborations: Boris Engels has collaborated with esteemed professionals in the industry, including Jennifer Brogdon and Huijuan Song. Together, they have synergized their expertise to create groundbreaking inventions that have the potential to revolutionize the way we approach healthcare and technology.

Conclusion: Boris Engels stands as a beacon of innovation, inspiring generations of inventors to push the boundaries of what is possible in technology. His unwavering commitment to creating a sustainable future through his inventions solidifies his position as a true trailblazer in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…